




The relative strengths and weaknesses of Blueprint Medicines Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Blueprint Medicines Corp compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 2.0% points. The greatest weakness of Blueprint Medicines Corp is the variable Other Liabilities, reducing the Economic Capital Ratio by 101% points.

The company's Economic Capital Ratio, given in the ranking table, is 140%, being 73% points below the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	808,393
Cost of Goods Sold	8,540
Intangible Assets	0
Liabilities, Current	214,923
Liabilities, Non-Current	92,756
Other Assets	198,898
Other Compr. Net Income	6,948
Other Expenses	5,224
Other Liabilities	610,962
Other Net Income	-19,739
Other Revenues	249,380
Property and Equipment	41,959
Research and Development	427,720
Selling, General and Administrative Expense	295,141

Output Variable	Value in 1000 USD
Assets	1,049,250
Liabilities	918,641
Expenses	736,625
Revenues	249,380
Stockholders Equity	130,609
Net Income	-506,984
Comprehensive Net Income	-503,510
BaseVar	1,490,292
ECR before LimitedLiability	-22%
Economic Capital Ratio	140%